Karen M. Soares reported a sale of Clover Health Investments, Corp. Class A common stock on July 20, 2026, according to a Form 4 filed the same day. The filing shows that Soares sold 51,700 shares at a reported weighted-average price of $4.51 per share, implying total gross proceeds of approximately $233,167 before commissions, taxes, or other costs. The sale was made under a Rule 10b5-1 trading plan that Soares adopted on March 13, 2026. Such plans allow company insiders to schedule trades in advance under predetermined conditions, helping separate the transaction from later possession of material nonpublic information. The reported $4.51 price was not a single execution price. The filing notes that the shares were sold in multiple transactions at prices ranging from $4.46 to $4.59 per share. Soares undertook to provide Clover Health, any securityholder, or SEC staff with full details on the number of shares sold at each individual price upon request. The filing identifies the security as Clover Health Class A common stock and describes the transaction as a sale; the provided text does not include a transaction-code line or state Soares’s remaining beneficial ownership after the sale. The Form 4 was signed by Peter J. Rivas as attorney-in-fact for Karen M. Soares.